Preventive Cardiology
M-A | Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and CKD
1 Feb, 2023 | 13:06h | UTC
WHO | Five billion people unprotected from trans-fat leading to heart disease
24 Jan, 2023 | 14:44h | UTCNews Release: Five billion people unprotected from trans fat leading to heart disease – World Health Organization
Report: Countdown to 2023: WHO report on global trans-fat elimination 2022 – World Health Organization
Commentary: Five Billion People Exposed to Industrially Produced Trans Fats – Health Policy Watch
Related:
WHO: More than 3 billion people protected from harmful trans-fat in their food
Action Package: WHO Plan to Eliminate Trans-fatty Acids from Global Food Supply
WHO Draft Guideline: Saturated Fatty Acid and Trans-fatty Intake for Adults and Children
Banning trans fats in New York prevented thousands of heart attacks
Review | Cardiovascular outcomes in type 1 and type 2 diabetes
23 Jan, 2023 | 13:18h | UTCCardiovascular outcomes in type 1 and type 2 diabetes – Diabetologia
Commentary on Twitter
Useful review of Cardiovascular outcomes in type 1 and type 2 diabeteshttps://t.co/mDECkFbZCq pic.twitter.com/q7J74FkNgJ
— Prof Kamlesh Khunti (@kamleshkhunti) January 20, 2023
Article under a http://creativecommons.org/licenses/by/4.0/. License
M-A | Prospective association of daily steps with cardiovascular disease
10 Jan, 2023 | 14:29h | UTCProspective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis – Circulation (link to abstract – $ for full-text)
Commentaries:
CVD Benefits of Activity Seen Below Widely Quoted Step Goal in Older Adults – TCTMD
Heart health tip for older adults in 2023: Step it up a bit – University of Massachusetts Amherst
Commentary on Twitter
#OriginalResearch: In a meta-analysis of 8 studies, 6,000 to 9,000 steps/day was associated with 40% to 50% lower risk of CVD among older adults #AHAJournals https://t.co/fEA1EFyhTI pic.twitter.com/T6LXFGZoVb
— Circulation (@CircAHA) December 21, 2022
Cohort Study | Association of the triglyceride glucose index as a measure of insulin resistance with mortality and CVD
9 Jan, 2023 | 13:42h | UTCInvited Commentary: The triglyceride glucose index and cardiovascular disease outcomes – The Lancet Health Longevity
RCT | Chlorthalidone (12.5-25 mg) and Hydrochlorothiazide (25-50 mg) are similarly effective for the prevention of CVD in hypertensive patients.
16 Dec, 2022 | 13:49h | UTCChlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)
Related (news release and commentaries before publication): RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
Commentary on Twitter
Patients 65 years or older with hypertension who switched from chlorthalidone to hydrochlorothiazide did not have fewer major cardiovascular events or non–cancer-related deaths than those who continued receiving hydrochlorothiazide. https://t.co/9xAiSZzxio pic.twitter.com/bIVOOiVDve
— NEJM (@NEJM) December 14, 2022
Cohort Study | Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood.
9 Dec, 2022 | 13:11h | UTCLipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood – Circulation
Commentary: Lp(a) in Youth and Risk of ASCVD Outcomes in Adulthood – American College of Cardiology
Commentary on Twitter
#OriginalResearch Childhood Lp(a) levels are associated with significantly increased risk of develping ASCVD as adults @UTUpophealth @olraita #AHAJournals https://t.co/oqHv19QU6l pic.twitter.com/ByZmtRrXqy
— Circulation (@CircAHA) November 30, 2022
Cohort Study | Adding salt to foods linked to increased risk of cardiovascular disease.
6 Dec, 2022 | 14:04h | UTCAdding Salt to Foods and Risk of Cardiovascular Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Release: Shaking less salt on your food at the table could reduce heart disease risk – American College of Cardiology
Commentaries:
Adding Salt to Food and Risk of Cardiovascular Disease – American College of Cardiology
Lower Frequency of Adding Salt to Food Linked to Lower CVD Risk – HealthDay
M-A | Cardioprotective effects of influenza vaccination in patients with high risk of cardiovascular disease.
25 Nov, 2022 | 12:47h | UTCCardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis – European Journal of Preventive Cardiology (free for a limited period)
Related:
RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.
Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.
23 Nov, 2022 | 14:02h | UTCNews Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health
Cohort Study | Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease.
23 Nov, 2022 | 13:55h | UTCRelated:
AHA Scientific Statement | Polygenic risk scores for cardiovascular disease.
Cohort Study | Polygenic risk, midlife life’s simple 7, and lifetime risk of stroke.
Cohort Study: A polygenic risk score may improve risk stratification of coronary artery disease.
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.
Commentary on Twitter
A #Polygenic risk score improves the accuracy of a clinical risk score for #CoronaryArteryDisease
Read more about improved predictive accuracy for incident CAD in the #UKBiobank at #BMCMedicine https://t.co/8T5RaacnTj pic.twitter.com/vIhg9IGhRv
— BMC Medicine (@BMCMedicine) November 8, 2022
RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.
16 Nov, 2022 | 13:41h | UTCNews Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association
Commentaries:
Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine
Statins vs. supplements: New study finds one is ‘vastly superior’ to cut cholesterol – NPR
Cohort Study | Childhood adversity and cardiovascular disease in early adulthood.
16 Nov, 2022 | 13:29h | UTCChildhood adversity and cardiovascular disease in early adulthood: a Danish cohort study – European Heart Journal (free for a limited period)
Commentary from the author on Twitter
https://twitter.com/HulvejRod/status/1592520830155886593
Canadian guideline for the prevention and management of cardiovascular disease in primary care.
8 Nov, 2022 | 12:37h | UTCNews Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.
1 Nov, 2022 | 12:02h | UTCSeverity of obstructive coronary artery stenosis after pre-eclampsia – Heart
Related:
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
Cohort Study: Preeclampsia and Cardiovascular Disease
All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease
Gestational Hypertension and Future Risk of Cardiovascular Disease
M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.
26 Oct, 2022 | 14:32h | UTCCommentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News
Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.
20 Oct, 2022 | 12:25h | UTC
RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.
19 Oct, 2022 | 14:15h | UTC
Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.
18 Oct, 2022 | 12:58h | UTCTrends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)
Related Study: Study shows that the leading causes of hospitalization of adults with diabetes are changing.
Perspective | The polypill: from concept and evidence to implementation.
18 Oct, 2022 | 12:55h | UTCThe polypill: from concept and evidence to implementation – The Lancet (free registration required)
Related:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Cohort Study | Purpose in life (Ikigai) and employment status in relation to cardiovascular mortality.
14 Oct, 2022 | 14:06h | UTC
RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.
13 Oct, 2022 | 13:53h | UTCInvited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet
Commentary on Twitter
Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle
— Pradeep Natarajan (@pnatarajanmd) October 7, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.
11 Oct, 2022 | 13:29h | UTCSee also: DIAL Model Calculator
Review | Obesity and contraceptive use: impact on cardiovascular risk.
16 Sep, 2022 | 12:53h | UTCObesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure
News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology